PRDM6 promoter methylation as a potential epigenetic biomarker in BRCA-associated ovarian cancer

Basit Öğe Kaydı
dc.authorid0000-0001-8841-4352
dc.authorid0000-0002-0893-1251
dc.authorid0000-0003-4417-4005
dc.authorid0000-0001-6530-0942
dc.authorid0000-0002-8919-0482
dc.authorid0000-0001-8023-3223
dc.contributor.authorCömert, Numan
dc.contributor.authorŞükrüoğlu Erdoğan, Özge
dc.contributor.authorÇelik Demirbaş, Betül
dc.contributor.authorKılıç Erciyas, Seda
dc.contributor.authorDinç, Ahmet
dc.contributor.authorPasin, Özge
dc.contributor.authorYazıcı, Hülya
dc.contributor.authorTuncer, Şeref Buğra
dc.date.accessioned2025-11-09T09:47:50Z
dc.date.available2025-11-09T09:47:50Z
dc.date.issued2025
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyoloji Ana Bilim Dalı
dc.description.abstractBackground: Ovarian cancer (OC) remains one of the most lethal gynecologic malignancies, primarily due to late-stage diagnosis. Aberrant DNA methylation is critical in tumorigenesis and represents a promising avenue for biomarker development. We hypothesized that PR/SET domain 6 (PRDM6) methylation is associated with breast cancer gene (BRCA) mutation status in OC. Methods: Peripheral blood samples were collected from 387 patients with high-grade serous ovarian cancer, 50 individuals with benign ovarian conditions, and 100 healthy controls. DNA methylation was evaluated using methylation-sensitive restriction enzymes (MSREs) and subsequently analyzed by real-time polymerase chain reaction (PCR). Descriptive statistics were employed to summarize categorical and continuous variables. Associations between PRDM6 methylation and clinical parameters, including BRCA mutation status, cancer antigen 125 (CA-125) levels, and age, were statistically analyzed. Results: PRDM6 methylation was detected in 53.9% of OC patients, 60.0% of individuals with benign ovarian disease, and 37.0% of healthy controls. The methylation frequency in OC patients was significantly higher than in healthy controls (p = 0.005). PRDM6 promoter methylation was detected in 64.8% of BRCA-mutated OC patients compared to 50.3% of BRCA negative patients, indicating a significant association between BRCA mutation status and PRDM6 methylation (p = 0.016). No significant associations were found between PRDM6 methylation and age, menopausal status, or CA-125 levels. Conclusions: PRDM6 methylation may serve as a non-invasive biomarker for early detection in high risk populations, particularly in BRCA mutation carriers.
dc.description.sponsorshipThis study was funded by the Scientific Research Projects Coordination Unit of Istanbul University (Project number: TYL-2021-38160 and TOA-2020-35780). Bu çalışma İstanbul Üniversitesi Bilimsel Araştırma Projeleri Koordinasyon Birimi tarafından finanse edilmiştir (Proje numarası: TYL-2021-38160 ve TOA-2020-35780).
dc.identifier.citationCömert, N., Şükrüoğlu Erdoğan, Ö., Çelik Demirbaş, B., Kılıç Erciyas, S., Dinç, A., Pasin, Ö., Yazıcı, H., & Tuncer, Ş. B. (2025). PRDM6 promoter methylation as a potential epigenetic biomarker in BRCA-associated ovarian cancer. European Journal of Gynaecological Oncology, 46(10), pp. 21-30. https://doi.org/10.22514/ejgo.2025.128
dc.identifier.doi10.22514/ejgo.2025.128
dc.identifier.endpage30
dc.identifier.issn0392-2936
dc.identifier.issn2709-0086
dc.identifier.issue10
dc.identifier.startpage21
dc.identifier.urihttps://doi.org/10.22514/ejgo.2025.128
dc.identifier.urihttps://hdl.handle.net/20.500.13055/1178
dc.identifier.volume46
dc.identifier.wosWOS:001596660200004
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expanded
dc.institutionauthorYazıcı, Hülya
dc.institutionauthorid0000-0001-8023-3223
dc.language.isoen
dc.publisherMRE Press
dc.relation.ispartofEuropean Journal of Gynaecological Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectOvarian Cancer
dc.subjectDNA Methylation
dc.subjectEpigenetic Biomarker
dc.subjectPRDM6 Methylation
dc.subjectBRCA Mutation
dc.titlePRDM6 promoter methylation as a potential epigenetic biomarker in BRCA-associated ovarian cancer
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
Tam Metin / Full Text
Boyut:
3.09 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Temel Tıp Bilimleri Bölümü Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu